Recent Advances and Prospects in the Isolation by Size of Epithelial Tumor Cells (ISET) Methodology
Recent Advances and Prospects in the Isolation by Size of Epithelial Tumor Cells (ISET) Methodology
复制标题
按上皮肿瘤细胞大小分离 (ISET) 方法学的最新进展和展望
DOI：
10.7785/tcrt.2012.500328
复制
发表时间：
2013-08-01
影响因子：
2.8
通讯作者：
Yu, Feng-Lei
中科院分区：
文献类型：
--
作者：
Ma, Yu-Chao;Wang, Li;Yu, Feng-Lei
目前用于鉴定和表征血流中数亿白细胞中的循环肿瘤细胞（CTC）和循环肿瘤微栓子（CTM）的技术可分为肿瘤标志物依赖性和非依赖性技术。上皮肿瘤细胞大小分离（ISET）是一种不依赖肿瘤标志物的技术，其中CTC通过过滤分离，而不使用肿瘤相关标志物，因为它们相对于循环血液白细胞的大小较大。ISET允许CTC和CTM的细胞形态学、免疫细胞学和遗传学表征。它提供了许多优点，包括细胞形态的保留;非抗原依赖性;通过免疫标记、荧光原位杂交和RNA/DNA分析进一步询问细胞的顺从性;分离CTM的能力;可靠性。因此，基于形态学分析和抗原非依赖性的ISET方法可以产生更准确和客观的表征上皮-间充质转化。我们可以通过使用异种移植物来评估化学疗法和放射疗法以及其他癌症靶向疗法的功效，所述异种移植物是用于ISET分离的CTC/CTM生物学的机制研究的合适模型。此外，基于ISET的新型装置可以大大提高对CTC/CTM的敏感性，并直接减少血液流动过程中CTC/CTM的数量，从而降低肿瘤复发和转移的可能性，同时保留正常血细胞。本文综述了ISET方法学的最新进展和展望，并对ISET方法学的发展提出了新的见解，对癌症患者的临床管理具有重要意义。
Current technologies to identify and characterize circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs) among hundreds of millions of leukocytes in the bloodstream can be classified into tumor-marker-dependent and -independent technology. Isolation by size of epithelial tumor cells (ISET) is a tumor-marker-independent technology, in which CTCs are isolated by filtration without use of tumor-associated markers, as a result of their large size relative to circulating blood leukocytes. ISET allows cytomorphological, immunocytological, and genetic characterization of CTCs and CTMs. It offers a number of advantages, including retention of cell morphology; non-antigen dependence; amenability of cells to further interrogation by immunolabeling, fluorescence in situ hybridization, and RNA/DNA analysis; ability to isolate CTMs; reliability. Therefore, morphological-analysis-based and antigen-independent ISET methodology can yield more accurate and objective characterization of epithelial-mesenchymal transition. We can evaluate efficacy of chemotherapy and radiotherapy and other cancer-targeting therapies by using xenografts that are suitable models for mechanistic studies of ISET-isolated CTC/CTM biology. In addition, a new ISET-based device could be designed to increase sensitivity to CTCs/CTMs greatly and reduce the number of CTCs/CTMs directly during the blood flow, thus decreasing the possibility of tumor recurrence and metastasis while retaining normal blood cells. This article reviews recent advances and prospects in ISET methodology and provides new insights into ISET methodology, with important implications for the clinical management of cancer patients.